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Abstract
A national recipient hemovigilance system was introduced in the United States in 2010, when 
voluntary enrollment began as part of the National Healthcare Safety Network (NHSN) 
Hemovigilance Module. NHSN is a secure, web-based surveillance system operated by the 
Centers for Disease Control and Prevention and used by US healthcare facilities to report a variety 
of patient safety information. The Hemovigilance Module is used for comprehensive monitoring 
of transfusion-related adverse events. Participating facilities can utilize analytic tools available 
within the module to identify opportunities for enhancing transfusion safety, evaluate the 
effectiveness of interventions, and compare facility specific transfusion-related data to aggregate 
national estimates. Data may be voluntarily shared by facilities with external partners for patient 
safety improvement initiatives and to fulfill reporting mandates. We describe the key 
characteristics of the Hemovigilance Module, highlight the benefits for participating facilities, and 
discuss the use of reported data for establishing national estimates of transfusion-associated 
adverse events to identify gaps in transfusion safety and opportunities for interventions. National 
hemovigilance systems are essential to recognize gaps in transfusion safety and identify 
opportunities for interventions to improve patient safety and outcomes.
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Introduction
With the emergence of HIV as a threat to blood safety in the 1980s, mitigating risks to 
transfusion recipients has been a worldwide public health priority.1,2 Hemovigilance, which 
includes surveillance activities encompassing the entire transfusion process, was 
implemented as a national program in France in 1994, followed by similar programs in other 
European countries, Canada, and elsewhere.1,3–6 In the United States, hospital transfusion 
services report different hemovigilance activities to federal, state, and non-governmental 
organizations to fulfill mandatory reporting requirements or as part of patient safety 
improvement initiatives.7–10 Although these hemovigilance activities provide valuable 
patient safety data, a national hemovigilance system was not introduced in the United States 
until recently.
In 2006, the Advisory Committee on Blood Safety and Availability (ACBSA) recommended 
that the Department of Health and Human Services (HHS) coordinate, support, and facilitate 
biovigilance in partnership with the private sector. The ACBSA defined biovigilance as a 
“comprehensive and integrated national patient safety program to collect, analyze, and 
report on the outcomes of collection and transfusion and/or transplantation of blood 
components and derivatives (i.e., hemovigilance), cells, tissues, and organs.”11 In 2007, to 
specifically address the hemovigilance aspect, the Centers for Disease Control and 
Prevention (CDC), in collaboration with transfusion medicine experts convened by AABB, 
developed the data requirements for a national recipient hemovigilance system as part of 
CDC’s National Healthcare Safety Network (NHSN).12
NHSN is a secure, web-based surveillance system used by more than 12,000 U.S. healthcare 
facilities to report healthcare-associated infections (HAIs), central line insertion practices, 
antimicrobial use and resistance, healthcare personnel influenza vaccination coverage, and 
other patient safety data. This system integrated previously existing CDC surveillance 
systems used to capture data on nosocomial infections (National Nosocomial Infections 
Surveillance System), occupational exposures and infections among healthcare personnel 
(National Surveillance System for Healthcare Workers), and HAIs among hemodialysis 
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patients (Dialysis Surveillance Network). NHSN includes the Hemovigilance Module, 
which is used for comprehensive monitoring of transfusion-related adverse events in US 
healthcare facilities and is intended to assist facilities with internal blood utilization 
practices and transfusion safety monitoring while allowing facilities to compare adverse 
events trends to national level data through analytic and benchmarking features. 
Furthermore, the module is intended to reduce the reporting burden on facilities by 
facilitating data sharing with external groups for mandatory or voluntary quality 
improvement reporting requirements. The Hemovigilance Module was piloted by nine 
facilities in 2009 and was opened for voluntary national enrollment in 2010 (Figure 1).
NHSN Hemovigilance Module Data Reporting
Any transfusing healthcare facility in the U.S. may submit recipient hemovigilance data to 
CDC, and by enrolling, agrees to adhere to the Hemovigilance Module protocol for 
continuous surveillance for a minimum of 12 months. Participants submit an annual facility 
survey, individual reports on adverse transfusion reactions, incidents (i.e., errors and 
accidents) associated with adverse reactions, and monthly counts of transfused or discarded 
components and patient samples collected for cross-match (Figure 2). Data are submitted 
electronically to CDC through NHSN’s secure, web-based application. Additional optional 
fields are also available in the application and may be used to conduct facility-specific 
surveillance, though they are not included in national aggregate analysis by CDC.
Annual Facility Survey
The annual facility survey is completed upon enrollment in the Hemovigilance Module and 
each calendar year thereafter. The survey collects facility characteristics such as hospital 
ownership, setting, and trauma level; the number of beds served by the transfusion service; 
hospital and laboratory accreditations; and the number of surgeries performed each year. 
Transfusion service characteristics and blood bank practices such as the number of 
transfusion service staff members employed; number of blood components transfused 
annually; inventory management systems in use; and cross-matching methods used are also 
captured in the survey. In addition to providing insight into blood banking practices, survey 
data allow CDC to classify facilities for comparisons in aggregate data analyses.
Monthly Denominators
Participating facilities report monthly totals of transfused or discarded components by 
component type (whole blood, red blood cell, platelet, plasma, and cryoprecipitate), 
collection method (apheresis or whole blood derived), modification methods (irradiation or 
leukocyte reduction), and unit size (full unit or aliquot). The number of patient samples 
collected and total crossmatch procedures performed are also reported monthly. Total 
patients transfused each month may be optionally reported.
Adverse Reactions
The protocol provides case definition criteria for 12 adverse reactions – transfusion-
associated circulatory overload, transfusion-related acute lung injury, transfusion-associated 
dyspnea, allergic, hypotensive, febrile non-hemolytic, acute hemolytic, delayed hemolytic, 
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delayed serologic, transfusion-associated graft vs. host disease, post-transfusion purpura, 
and transfusion-transmitted infection – and general criteria for patient events that can be 
classified as ‘unknown’ or ‘other’ reactions. Facilities use the ‘unknown’ category when the 
patient experienced transfusion-related symptoms, but the medical event could not be 
identified or classified within the specified categories. The ‘other’ category is used when the 
patient experienced a recognized transfusion-related adverse reaction that is not defined by 
the protocol such as transfusion-associated gut injury. Reactions are reported with an 
imputability designation, which is the likelihood that the reaction is attributable to the 
transfusion, and a severity grade (Figure 3). The adverse reaction record includes general 
demographic information, reaction details, clinical investigation results, patient outcome, 
and transfused component details. Adverse reactions are reported after an investigation has 
been completed in the hospital. Participants report all of the 12 CDC-defined adverse 
reactions that meet definite, probable, or possible imputability criteria that occur in their 
facility. Data reported optionally, such as non-severe allergic reactions, can be used by the 
reporting facility for their own purposes but are not included in national aggregate analyses 
by CDC.
Incidents
More than 150 incident codes are provided in the surveillance protocol to describe 
transfusion-related errors and accidents that occur throughout the transfusion process. These 
codes were adapted from the US Medical Event Reporting System for Transfusion Medicine 
(MERS TM) and the Canadian Transfusion Errors Surveillance System (TESS) incident 
code sets.13,14 The incident record includes details on incident discovery, occurrence, and 
hospital investigation results. Facilities participating in the Hemovigilance Module must 
report incidents associated with adverse reactions. In addition, facilities may use the system 
to report incidents not associated with an adverse reaction for their own facility use and 
analysis.
Making use of Hemovigilance Data
NHSN offers analytic options to participants for their facility-specific transfusion practice 
and safety monitoring. For example, facilities can create monthly adverse reaction rate bar 
charts to establish baseline occurrence trends and then monitor the effect of prevention 
efforts. Regular monitoring of adverse reaction rates allow for the recognition of blood 
safety threats that may occur, as well. Participating facilities can create data tables of 
specific adverse reactions or all adverse reactions occurring per 10,000 transfused blood 
components. Rates may also be calculated for sample-related incidents occurring per 10,000 
samples collected or component-related incidents occurring per 10,000 components 
transfused. These functionalities also allow facilities to compare their rates with aggregate 
adverse event rates published by CDC.
CDC will produce national estimates of transfusion-associated adverse events through 
aggregate analysis of submitted data to identify gaps in transfusion safety that can inform 
the development of public health interventions. The national data can then be used to 
evaluate the effectiveness of interventions as has occurred in other countries. For example, 
in response to deaths due to bacterial contamination reported to the French hemovigilance 
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network, new guidelines for skin disinfection methods were introduced that resulted in a 
decrease in septic transfusion reactions.3 Similarly, in Quebec, transfusion-transmitted 
bacterial infection rates led to the implementation of diversion segments and post-collection 
culturing of platelets that resulted in a decline in bacterial infection transmissions, all of 
which were monitored through the national hemovigilance program.15 Furthermore, 
hemovigilance data reported to the UK Serious Hazards of Transfusion system revealed that 
post-transfusion purpura and transfusion-associated graft vs. host disease could be prevented 
through universal leukocyte reduction.16 These patient safety interventions are now common 
transfusion practice across industrialized countries.
Participating facilities can also share Hemovigilance Module data with external partners 
through a function built into NHSN to satisfy reporting requirements for patient safety 
improvement initiatives or reporting mandates without the added burden of entry into 
multiple systems. Using this function, facilities can share varying subsets of data with 
multiple groups for various purposes. One example is the recent mandate by the 
Massachusetts Department of Public Health (MDPH) that requires all licensed hospital 
blood banks and transfusion services in the state to report blood bank activity reports to the 
Hemovigilance Module, which is made immediately available to MDPH within the NHSN 
framework. These facilities can track their own transfusion safety indicators and contribute 
to national hemovigilance while also meeting their state reporting requirement with MDPH.7
Conclusion
The NHSN Hemovigilance Module is the only national transfusion safety surveillance 
system in the United States and also serves as a tool for facilities to monitor and improve 
their own transfusion safety practices. The system is free to use by any transfusing 
healthcare facility in the United States. Reporting requirements have been streamlined to 
make it easier for facilities to take advantage of system features. Facilities can use the 
analytic tools within the application to drive facility-level transfusion safety initiatives for 
safety improvements, evaluate the effectiveness of these initiatives, and compare their 
progress to others nationally.
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Figure 1. Development timeline of the NHSN Hemovigilance Module
The concept for the Hemovigilance Module was introduced in 2006 with development 
beginning in 2007 in collaboration with expert groups convened by AABB. In 2009, the 
module was piloted in 9 facilities, and national enrollment began in January 2010. In 2011, 
the total number of facilities that enrolled in the module reached 100. The first progress 
reports were presented in 2012. In 2013, in an effort to increase participation, the protocol 
was simplified such that near-miss and no-harm incidents were no longer required.
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Figure 2. NHSN Hemovigilance Module Data Flow Chart
Participating hospitals report an annual survey, components transfused monthly, adverse 
transfusion reactions, and incidents associated with reactions to the NHSN Hemovigilance 
Module. CDC conducts national aggregate data analyses. Facilities may also share their data 
with groups within NHSN. Groups may include patient safety organizations (PSO), hospital 
systems, and state and local health departments. These data can be used for benchmarking, 
allowing hospitals to monitor transfusion processes and outcomes, or fulfilling state and 
local mandatory reporting. Facilities may use the data for facility-level process 
improvements.
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Figure 3. General case definition criteria for an adverse transfusion reaction to NHSN 
Hemovigilance Module
The NHSN Hemovigilance Module protocol specifies the case definition for 12 adverse 
transfusion reactions based on the presence of signs, symptoms, and laboratory and 
radiographic data. Reactions are reported with a severity designation based on clinical 
outcomes. Imputability designations which specify the likelihood that reaction was 
associated with the transfusion event are also reported.
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